Price$22.68+0.39 (+1.77%)
01:45 PM07:45 PM
News · 26 weeks56+400%
2026-03-012026-08-23
Mix2790d
- Insider12(44%)
- SEC Filings5(19%)
- Other5(19%)
- Analyst2(7%)
- Earnings2(7%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)
- INSIDERDirector Magistretti Elisabetta sold $41,084 worth of Ordinary Shares (2,045 units at $20.09), decreasing direct ownership by 41% to 2,930 units (SEC Form 4) to cover taxes4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERChief Financial Officer Dal Lago Marco sold $84,559 worth of Ordinary Shares (4,209 units at $20.09), decreasing direct ownership by 5% to 81,144 units (SEC Form 4) to cover withholding tax4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Santel Luciano sold $40,642 worth of Ordinary Shares (2,023 units at $20.09), decreasing direct ownership by 30% to 4,739 units (SEC Form 4) (withholding tax)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)
- PRStevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026- The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increased 60 basis points to 28.7%. Adjusted EBITDA margin increased 280 basis points to 26.0%. The Company completed the divestiture of its California-ba
- PRLiraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European CountriesThe regulatory approvals cover therapies for diabetes and weight management, further expanding the commercial adoption of Stevanato Group's proprietary Alina® pen injector platform across Europe. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. This press r
- PRStevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-r
- INSIDERDirector Balachandran Madhavan was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 5% to 69,458 units (SEC Form 4) to satisfy withholding obligation4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERChief Financial Officer Dal Lago Marco was granted 2,356 units of Ordinary Shares and converted options into 7,997 units of Ordinary Shares, increasing direct ownership by 14% to 85,353 units (SEC Form 4)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Lin Sue-Jean was granted 4,975 units of Ordinary Shares, increasing direct ownership by 249% to 6,975 units (SEC Form 4)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Morel Donald E Jr was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 10% to 37,424 units (SEC Form 4) (tax withholding)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Santel Luciano was granted 4,975 units of Ordinary Shares, increasing direct ownership by 278% to 6,762 units (SEC Form 4)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Magistretti Elisabetta was granted 4,975 units of Ordinary Shares (SEC Form 4)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDEROfficer Stocchi Mauro was granted 2,101 units of Ordinary Shares and converted options into 6,586 units of Ordinary Shares, increasing direct ownership by 2% to 413,629 units (SEC Form 4)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Flynn Karen was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 153% to 5,757 units (SEC Form 4) (tax withholding)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Federici William J was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 15% to 26,991 units (SEC Form 4) to satisfy withholding obligation4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- ANALYSTTD Cowen initiated coverage on Stevanato Group S.p.A. with a new price targetTD Cowen initiated coverage of Stevanato Group S.p.A. with a rating of Buy and set a new price target of $25.00
- PRStevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight ManagementThe fixed-dose, multi-use pen injector platform features a pull-push mechanism designed to reduce use error while supporting delivery volumes up to 0.75 mL Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608096966/en/Deora™ is Stevanato Group's multi-use, fi
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- PRStevanato Group Announces Results of Ordinary and Extraordinary Shareholders' MeetingAll Resolutions Proposed to Shareholders Passed Stevanato Group S.p.A. (NYSE:STVN) (the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders ("Shareholders' Meeting") held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, the Shareholders' Meeting are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.steva
STVN FAQ
8 questionsWhat does Stevanato Group S.p.A. do?
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.Where does STVN stock trade?
Stevanato Group S.p.A. (STVN) is listed on NYSE.What sector and industry is STVN in?
Stevanato Group S.p.A. operates in the Health Care sector, Medical/Dental Instruments industry.When did Stevanato Group S.p.A. go public?
Stevanato Group S.p.A. (STVN) completed its IPO in 2021.Does STVN pay a dividend?
STVN's most recent ex-dividend date was 2026-06-11 with a cash dividend of $0.05 per share. No future ex-date is on file yet.What are analysts saying about STVN?
Stevanato Group S.p.A. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $2500.00 price target on 2026-06-16. Recent price targets range from $2100.00 to $3300.00.What companies are similar to STVN?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare STVN side-by-side with any of them on Quantisnow.How can I track STVN on Quantisnow?
Quantisnow aggregates Stevanato Group S.p.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STVN to receive live email and push alerts on every new disclosure.